FIELD: medicine.
SUBSTANCE: blood test of patient is carried out. In addition to this following indicators are defined at examination: age, social status, accompanying diseases, quantity of blood monocytes, speed of subsidence of erythrocytes (SSE), total bilirubin of blood, blood creatin, specific weight of urine, urine reaction. Then forecasting index (FI) for each indicator is defined. Age at marker - before 20 years FI equal to (0) is established in the system, at marker 20-29 years - equal to (-10), at marker 30-39 years - equal to (-7), at marker 40-49 years - equal to(+4), at marker 50-59 years - equal to (+3), at marker 60-69 years - equal to (+2), at marker 70-79 years - equal to (+4), at marker 80 and more years - equal to (-3). Social status at marker - workers FI equal to (+4) is established in the system, at marker employees - equal to (-1), at marker pupils - equal to (0), at marker the unemployed - equal to (-12), at marker pensioners and disabled workers (DW) - equal to (+1). Accompanying diseases at marker - diseases of gastroenteric tract (GET) FI equal to (-10) is established in the system, at marker of disease of cardiovascular system - equal to (+2), at marker of disease of endocrine system - equal to (+1.5), at marker of disease of respiratory system - equal to (0), at marker of disease of locomotor apparatus - equal to (0), at marker of disease of urogenital system - equal to (-13), at marker of combination of accompanying diseases - equal to (-1), at marker of absence of accompanying diseases - equal to (+2). Blood monocytes, at marker - not present, FI equal to (0) is established in the system, at marker of 1-3% - equal to (-2.5), at marker of 4-6% - equal to (+2), at marker of 7-10% - equal to (+2.5), at marker more than 10% - equal to (0). Blood sedimentation rate at marker - 1-10 mm per hour FI equal to (-1) is established in the system, at marker of 11-20 mm per hour - equal to (-3), at marker of 21-30 mm per hour - equal to (+7), at marker of 31-40 mm per hour - equal to (0), at marker more than 40 mm per hour - equal to (0). Total bilirubin at marker - less than 8.8 mcmol/l FI equal to (0) is established in the system, at marker of 8.8-17 mcmol per l. - equal to (-1), at marker more than 17 mcmol per l.- equal to (+5.5). Creatinin at marker - less than 0.07 mcmol per l. FI equal to (+11) is established in the system, at marker 0.07-0.17 - equal to (-3), at marker more than 0.17 mcmol/l - equal to (0). Specific weight of urine at marker less-1008 FI equal to (0) is established in the system, at marker 1008-1026 - equal to (+2), at marker more than 1026 - equal to (+6). Urine reaction at marker - sour, FI equal to (+3) is established in the system, at marker neutral - equal to (-3), at marker alkaline - equal to (-12). If FI sum is from (-54.5) to (-21.5) low probability of cancer of mammary gland is predicted, if the sum is from (+11) to (+44.5) high probability of cancer of mammary gland is predicted.
EFFECT: working out simple means of mammary gland cancer diagnostics initially.
4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DIFFERENTIAL DIAGNOSTICS OF MAMMARY GLAND CANCER AND CENTRAL BROKEN BREAST | 2007 |
|
RU2336823C1 |
MEANS FOR BREAST CANCER PREDICTION | 2016 |
|
RU2631940C1 |
METHOD OF PREDICTING RISK OF DEVELOPING TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2811257C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING BREAST CANCER IN WOMEN BASED ON DATA ON INTERLOCUS INTERACTIONS | 2023 |
|
RU2815932C1 |
METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF THE LUMINAL SUBTYPE OF BREAST CANCER | 2023 |
|
RU2795720C1 |
METHOD FOR PREDICTING THE RISK OF DEVELOPING BREAST CANCER IN WOMEN USING MOLECULAR GENETIC DATA | 2022 |
|
RU2795897C1 |
METHOD FOR PREDICTION OF BREAST CANCER RISK DEVELOPMENT IN OBESE WOMEN | 2022 |
|
RU2795244C1 |
METHOD FOR PREDICTION OF BREAST CANCER RISK DEVELOPMENT IN NON-OBESE WOMEN | 2023 |
|
RU2795726C1 |
METHOD FOR PREDICTING RISK OF GRADE 3 MALIGNANCY OF TUMOR CELLS IN BREAST CANCER | 2023 |
|
RU2823459C1 |
METHOD FOR PREDICTION OF INCREASED RICK OF DEVELOPING STAGE 1-2 BREAST CANCER IN WOMEN BASED ON POLYMORPHISM OF THE MATRIX METALLOPROTEINASE 9 GENE | 2022 |
|
RU2795100C1 |
Authors
Dates
2008-10-27—Published
2007-04-05—Filed